Required Director of Search & Evaluation, Business Development
In this role, you will proactively identify best‑in‑class assets, lead rigorous scientific and clinical evaluations, and drive cross‑functional diligence to enable high‑quality, strategic partnering decisions. You will operate at the intersection of science, strategy, and execution, working in close partnership with Medical, Regulatory, and senior leadership to support disciplined growth and long‑term value creation.
Responsibilities
Proactively screen, source, and prioritize best‑in‑class late‑stage assets from Phase 2 through marketed products across rare and severe diseases, leveraging multiple platforms, databases, and industry sources.
Build and manage a robust and high‑quality pipeline of partnership opportunities aligned with our long‑term growth strategy.
Lead rigorous scientific and clinical evaluations by assessing clinical data versus current standard of care, mechanism of action differentiation, regulatory pathways, and competitive landscape.
Develop clear and data‑driven Target Product Profiles (TPPs) to support scientific, clinical, and strategic positioning.
Conduct comprehensive research, including literature review and data synthesis, to deeply understand disease biology, unmet need, and therapeutic value.
Engage directly with Key Opinion Leaders, clinical investigators, and external experts to validate assumptions and strengthen scientific and clinical assessments.
Drive cross‑functional diligence by partnering closely with function leads, Medical and Regulatory, Commercial, Legal, Finance, and other relevant stakeholders.
Support transaction strategy and execution by providing scientific and clinical input into transaction strategies, diligence materials, and contractual discussions.
Prepare clear, concise, and decision‑ready materials, including evaluation summaries, one‑pagers, presentations, and business cases for senior leadership and governance forums.
Continuously refine and strengthen Search and Evaluation processes, criteria, and scientific convergence frameworks to improve rigor, consistency, and speed of decision‑making.
Act as a trusted thought partner to leadership by surfacing insights, risks, and recommendations that directly influence portfolio strategy and our growth trajectory.
Represent us externally in partnering discussions, scientific meetings, and industry conferences to strengthen our visibility and network.
In this role, you will proactively identify best‑in‑class assets, lead rigorous scientific and clinical evaluations, and drive cross‑functional diligence to enable high‑quality, strategic partnering decisions. You will operate at the intersection of science, strategy, and execution, working in close partnership with Medical, Regulatory, and senior leadership to support disciplined growth and long‑term value creation.
Responsibilities
Proactively screen, source, and prioritize best‑in‑class late‑stage assets from Phase 2 through marketed products across rare and severe diseases, leveraging multiple platforms, databases, and industry sources.
Build and manage a robust and high‑quality pipeline of partnership opportunities aligned with our long‑term growth strategy.
Lead rigorous scientific and clinical evaluations by assessing clinical data versus current standard of care, mechanism of action differentiation, regulatory pathways, and competitive landscape.
Develop clear and data‑driven Target Product Profiles (TPPs) to support scientific, clinical, and strategic positioning.
Conduct comprehensive research, including literature review and data synthesis, to deeply understand disease biology, unmet need, and therapeutic value.
Engage directly with Key Opinion Leaders, clinical investigators, and external experts to validate assumptions and strengthen scientific and clinical assessments.
Drive cross‑functional diligence by partnering closely with function leads, Medical and Regulatory, Commercial, Legal, Finance, and other relevant stakeholders.
Support transaction strategy and execution by providing scientific and clinical input into transaction strategies, diligence materials, and contractual discussions.
Prepare clear, concise, and decision‑ready materials, including evaluation summaries, one‑pagers, presentations, and business cases for senior leadership and governance forums.
Continuously refine and strengthen Search and Evaluation processes, criteria, and scientific convergence frameworks to improve rigor, consistency, and speed of decision‑making.
Act as a trusted thought partner to leadership by surfacing insights, risks, and recommendations that directly influence portfolio strategy and our growth trajectory.
Represent us externally in partnering discussions, scientific meetings, and industry conferences to strengthen our visibility and network.
Requirements:
An advanced degree in Life Sciences (PhD or MD) is required; an MBA or additional business training is a strong advantage.
At least eight years of relevant experience in Search and Evaluation, Business Development, Licensing, Corporate Development, venture capital, or related partnering roles within pharma or biotech.
Proven experience evaluating late‑stage assets from Phase 2 through marketed products, preferably in rare and severe diseases.
Strong understanding of drug development, clinical data interpretation, regulatory pathways, and competitive dynamics.
Demonstrated experience developing Target Product Profiles and comparing clinical data to existing standards of care.
Proven ability to lead cross‑functional diligence teams and work closely with Business Development deal leads throughout the transaction lifecycle.
Strong scientific credibility with the ability to engage confidently with Key Opinion Leaders, investigators, and senior internal stakeholders.
Excellent written and verbal communication skills in English, with the ability to create clear, concise, executive‑level decision materials.
Strong organizational skills and the ability to manage multiple complex evaluations in parallel in a fast‑paced environment.
An ownership‑driven, hands‑on leadership style with strong strategic thinking, sound judgment, and business acumen.
An advanced degree in Life Sciences (PhD or MD) is required; an MBA or additional business training is a strong advantage.
At least eight years of relevant experience in Search and Evaluation, Business Development, Licensing, Corporate Development, venture capital, or related partnering roles within pharma or biotech.
Proven experience evaluating late‑stage assets from Phase 2 through marketed products, preferably in rare and severe diseases.
Strong understanding of drug development, clinical data interpretation, regulatory pathways, and competitive dynamics.
Demonstrated experience developing Target Product Profiles and comparing clinical data to existing standards of care.
Proven ability to lead cross‑functional diligence teams and work closely with Business Development deal leads throughout the transaction lifecycle.
Strong scientific credibility with the ability to engage confidently with Key Opinion Leaders, investigators, and senior internal stakeholders.
Excellent written and verbal communication skills in English, with the ability to create clear, concise, executive‑level decision materials.
Strong organizational skills and the ability to manage multiple complex evaluations in parallel in a fast‑paced environment.
An ownership‑driven, hands‑on leadership style with strong strategic thinking, sound judgment, and business acumen.
This position is open to all candidates.
